Recap: Eli Lilly Q4 Earnings

 

Shares of Eli Lilly LLY decreased 0.3% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 58.96% year over year to $2.75, which beat the estimate of $2.35.

Revenue of $7,440,000,000 higher by 21.69% from the same period last year, which beat the estimate of $7,290,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $7.75 and $8.40.

The upcoming fiscal year's revenue expected to be between $26,500,000,000 and $28,000,000,000.

Conference Call Details

Date: Jan 29, 2021

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ku6m85kq

Technicals

52-week high: $213.23

Company's 52-week low was at $117.06

Price action over last quarter: Up 59.55%

Company Profile

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!